Business Context and Reporting Period
Company: Aytu BioScience, Inc. (AYTU)
Filing Type: Form 8-K (Current Report)
Date of Report: June 27, 2020
Reporting Period: Event-based report regarding strategic partnerships and product distribution.
Key Financial Metrics
This filing is a current report regarding corporate events and does not contain financial statements. The text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Strategic Developments
- New Collaboration: Signed a letter of intent with Biolidics, Limited to negotiate a Joint Development Agreement for a new SARS-CoV-2 diagnostic test.
- Termination of Agreement: Terminated the existing distribution agreement with Biolidics, effective June 27, 2020, in connection with the planned joint development.
- Refunds: Biolidics agreed to return all monies paid by Aytu for inventory orders placed but not received.
- Regulatory Action: Biolidics has begun voluntarily withdrawing its application to the US FDA for Emergency Use Authorization (EUA) pursuant to the FDA Serology Test Policy.
- Supply Chain Continuity: The Company maintains a distribution agreement with L.B. Resources, Limited to source FDA EUA-authorized "Orient Gene Test Kits." Management states this termination does not materially affect the supply of test kits.
Guidance, Outlook, and Risks
Outlook: Management believes a next-generation SARS-CoV-2 test may address evolving clinical needs. The Company expects to have adequate supply of Orient Gene Test Kits now and in the future.
Risks and Contingencies:
- No assurance that the Joint Development Agreement with Biolidics will be finalized.
- No assurance that a new diagnostic test will be successfully developed or commercialized.
- Risks regarding FDA clearance for any new test.
- Market acceptance risks due to increased scrutiny on the accuracy of serology tests.
- Supply chain risks regarding the ability to enforce the exclusive distribution agreement with Orient Gene.
Investor Verification Checklist
- Confirm whether the definitive Joint Development Agreement with Biolidics is executed.
- Verify the status of the voluntary withdrawal of Biolidics' FDA EUA application.
- Monitor the volume and reliability of supply for the Orient Gene Test Kits via L.B. Resources.
- Track any future announcements regarding the development timeline of the proposed new SARS-CoV-2 test.
- Review the Company's latest 10-K or 10-Q for actual financial performance data, as this 8-K contains no financial metrics.